Cardiovascular Safety and Bleeding Risk Associated with Nonsteroidal Anti-Inflammatory Medications in Patients with Cardiovascular Disease

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Current Cardiology Reports

• Publication date

  2017-01-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11886-017-0814-5PMID 28138824
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.

  2016cited by this paper
• Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology.

  2016cited by this paper
• Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction.

  2015cited by this paper
• 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

  2014cited by this paper
• Relation of nonsteroidal anti-inflammatory drugs to serious bleeding and thromboembolism risk in patients with atrial fibrillation receiving antithrombotic therapy: a nationwide cohort study.

  2014cited by this paper
• Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications.

  2014cited by this paper
• Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin.

  2014cited by this paper
• Nonsteroidal Anti-Inflammatory Drugs and Cardiovascular Outcomes in Women: Results From the Women’s Health Initiative

  2014cited by this paper
• 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

  2014cited by this paper
• Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials

  2013cited by this paper
• Duration of Treatment With Nonsteroidal Anti-Inflammatory Drugs and Impact on Risk of Death and Recurrent Myocardial Infarction in Patients With Prior Myocardial Infarction: A Nationwide Cohort Study

  2011cited by this paper
• Bleeding risk in patients with atrial fibrillation: the AMADEUS study.

  2011cited by this paper
• Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis

  2011cited by this paper
• Harmful effects of NSAIDs among patients with hypertension and coronary artery disease.

  2011cited by this paper
• Cardiovascular and Gastrointestinal Safety of NSAIDs: A Systematic Review of Meta‐Analyses of Randomized Clinical Trials

  2011cited by this paper
• Cause-Specific Cardiovascular Risk Associated With Nonsteroidal Antiinflammatory Drugs Among Healthy Individuals

  2010cited by this paper
• Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.

  2010cited by this paper
• Non‐steroidal anti‐inflammatory drugs and cardiac failure: meta‐analyses of observational studies and randomised controlled trials

  2008cited by this paper
• Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial.

  2008cited by this paper
• Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib

  2007cited by this paper
• Withdrawal of COX-2 selective inhibitors rofecoxib and valdecoxib: impact on NSAID and gastroprotective drug prescribing and utilization*

  2007cited by this paper
• Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association.

  2007cited by this paper
• Scientific Statement From the American Heart Association Use of Nonsteroidal Antiinflammatory Drugs : An Update for Clinicians: A

  2007cited by this paper
• Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.

  2006cited by this paper
• Cardiovascular and Cerebrovascular Events in the Randomized, Controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)

  2006cited by this paper
• Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials

  2006cited by this paper
• Risk of Death or Reinfarction Associated With the Use of Selective Cyclooxygenase-2 Inhibitors and Nonselective Nonsteroidal Antiinflammatory Drugs After Acute Myocardial Infarction

  2006cited by this paper
• Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.

  2006cited by this paper
• Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities.

  2005cited by this paper
• Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery.

  2005cited by this paper
• Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure.

  2005cited by this paper
• Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.

  2005cited by this paper
• Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis

  2005cited by this paper
• Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.

  2004cited by this paper
• Combined Anticoagulant–Antiplatelet Use and Major Bleeding Events in Elderly Atrial Fibrillation Patients

  2004cited by this paper
• ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients Wi

  2004cited by this paper
• Effect of ibuprofen on cardioprotective effect of aspirin.

  2003cited by this paper
• Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial.

  2002cited by this paper
• The coxibs, selective inhibitors of cyclooxygenase-2.

  2001cited by this paper
• Risk of cardiovascular events associated with selective COX-2 inhibitors.

  2001cited by this paper
• Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

  2000cited by this paper
• Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

  2000cited by this paper
• Effects of warfarin, aspirin and the two combined, on mortality and thromboembolic morbidity after myocardial infarction. The WARIS-II (Warfarin-Aspirin Reinfarction Study) design.

  2000cited by this paper
• A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure.

  1993cited by this paper

• Chrysotoxine Attenuates Key Atherogenic Processes via Antioxidant, Anti-Inflammatory, and COX-Dependent Antiplatelet Mechanisms

  2026cites this paper
• Advances in colorectal cancer screening and detection: a narrative review on biomarkers, imaging and preventive strategies

  2025cites this paper
• Migraine and cardiovascular disease: what cardiologists should know.

  2023cites this paper
• Colorectal Cancer Chemoprevention: A Dream Coming True?

  2023cites this paper
• Increased Risk of Cardio-Cerebrovascular Diseases in Migraine Patients: A Nationwide Population-Based, Longitudinal Follow-Up Study in South Korea

  2022cites this paper
• Improving the efficacy of Cyclooxegenase-2 inhibitors in the management of oral cancer: Insights into the implementation of nanotechnology and mucoadhesion

  2021cites this paper
• Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets

  2021cites this paper
• The effect of perioperative non-steroidal anti-inflammatory drugs and male sex on the recurrence rates after chronic subdural hematoma evacuation.

  2021cites this paper
• Hypertension and Migraine: Time to Revisit the Evidence

  2021cites this paper
• Effects of Arachidonic Acid Metabolites on Cardiovascular Health and Disease

  2021cites this paper
• Chemoprevention of Colorectal Cancer.

  2020cites this paper
• Evaluation of the community pharmacists’ performance in the screening of non-steroidal anti-inflammatory drugs risks in Saudi Arabia

  2020cites this paper
• Geriatric Pharmacology

  2020cites this paper
• L-Type Amino Acid Transporter 1-Utilizing Prodrugs of Ketoprofen Can Efficiently Reduce Brain Prostaglandin Levels

  2020cites this paper
• Peptic ulcer disease

  2019cites this paper
• Migraine Headache: An Under‐Appreciated Risk Factor for Cardiovascular Disease in Women

  2019cites this paper
• Chronic pain and neuropathic pain among community-dwelling older adults in primary health care settings

  2019cites this paper
• Trends and patterns of analgesic prescribing in Malaysian public hospitals from 2010 to 2016: tramadol predominately used

  2018cites this paper
• Accounting for cardiovascular risk when prescribing NSAIDs

  2018cites this paper
• NSAID Use and Cardiovascular Disease - A Cautionary Tale.

  2017cites this paper
• Risk perception of NSAIDs in hospitalized patients in Greece.

  2017cites this paper